Anxo Pharmaceutical Co., Ltd.
Anxo Pharmaceutical Co., Ltd., a specialty pharmaceutical company, develops, manufactures, and sells pharmaceutical products for medical professionals and patients in Taiwan and internationally. The company offers prescription and over the counter drugs in various therapeutic areas, such as cardiovascular, metabolism, CNS, diabetic, respiratory, anti-infection, dermatology, nephrology, urology, o… Read more
Anxo Pharmaceutical Co., Ltd. (6677) - Total Liabilities
Latest total liabilities as of June 2025: NT$931.96 Million TWD
Based on the latest financial reports, Anxo Pharmaceutical Co., Ltd. (6677) has total liabilities worth NT$931.96 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Anxo Pharmaceutical Co., Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Anxo Pharmaceutical Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Anxo Pharmaceutical Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Anxo Pharmaceutical Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MorphoSys AG
PINK:MPSYF
|
USA | $2.09 Billion |
|
Lii Hen Industries Bhd
KLSE:7089
|
Malaysia | RM104.70 Million |
|
Circio Holding ASA
OL:CRNA
|
Norway | Nkr25.15 Million |
|
Openn Negotiation Limited
PINK:OPNNF
|
USA | $842.66K |
|
Primega Group Holdings Limited
NASDAQ:ZDAI
|
USA | $892.36K |
|
LiCycle Holdings Corp
NYSE:LICY
|
USA | $575.30 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Anxo Pharmaceutical Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.68 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.93 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Anxo Pharmaceutical Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Anxo Pharmaceutical Co., Ltd. (2019–2024)
The table below shows the annual total liabilities of Anxo Pharmaceutical Co., Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$968.21 Million | -4.64% |
| 2023-12-31 | NT$1.02 Billion | -11.28% |
| 2022-12-31 | NT$1.14 Billion | +5.28% |
| 2021-12-31 | NT$1.09 Billion | -1.33% |
| 2020-12-31 | NT$1.10 Billion | -9.77% |
| 2019-12-31 | NT$1.22 Billion | -- |